HomeInsightsStock Comparison

Cohance Lifesciences Ltd vs Sanofi India Ltd Stock Comparison

Cohance Lifesciences Ltd vs Sanofi India Ltd Stock Comparison

Last Updated on: Jun 04, 2025

Key Highlights

  • The Latest Trading Price of Suven Pharmaceuticals Ltd is ₹ 1020 as of 04 Jun 15:30.
  • The p/e ratio of Suven Pharmaceuticals Ltd changed from 8.1 to 57.3 over 5 quarters. This represents a CAGR of 378.34% The p/e ratio of Sanofi India Ltd changed from 30.8 to 0 over 7 quarters. This represents a CAGR of -100.00% .
  • The market cap of Suven Pharmaceuticals Ltd changed from ₹ 2564 crore to ₹ 17223 crore over 5 quarters. This represents a CAGR of 358.94% The market cap of Sanofi India Ltd changed from ₹ 18578 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% .
  • The revenue of Suven Pharmaceuticals Ltd for the Mar '25 is ₹ 412.59 crore as compare to the Dec '24 revenue of ₹ 322.86 crore. This represent the growth of 27.79% The revenue of Sanofi India Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 526.3 crore. This represent the decline of -100%.
  • The ebitda of Suven Pharmaceuticals Ltd for the Mar '25 is ₹ 84.13 crore as compare to the Dec '24 ebitda of ₹ 133.41 crore. This represent the decline of -36.94% The ebitda of Sanofi India Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 122 crore. This represent the decline of -100%.
  • The net profit of Suven Pharmaceuticals Ltd changed from ₹ 120.59 crore to ₹ 38.73 crore over 8 quarters. This represents a CAGR of -43.33% The net profit of Sanofi India Ltd changed from ₹ 190.4 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% .
  • The dividend payout of Suven Pharmaceuticals Ltd changed from 23.57 % to 0 % over 5 quarters. This represents a CAGR of -100.00% The dividend payout of Sanofi India Ltd changed from 175.77 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Suven Pharmaceuticals Ltd

  • Suven Pharmaceuticals Limited (SPL) is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
  • The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Suven Pharmaceuticals Limited was incorporated on 6 November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
  • The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.

About Sanofi India Ltd

  • Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
  • The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
  • The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
  • The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
  • It has its own manufacturing facility at Goa.

Suven Pharmaceuticals Ltd News Hub

News

Cohance Lifesciences' API Unit-IV clears USFDA inspection

Cohance Lifesciences has received the Establishment Inspection Report (EIR) from the Unite...

Read more

26 May 2025 08:46

News

Suven Pharmaceuticals allots 12.80 cr equity shares

Suven Pharmaceuticals has allotted 12,80,02,184 equity shares of the Company of face value...

Read more

09 May 2025 09:58

News

Suven Pharmaceuticals renamed as Cohance Lifesciences

Suven Pharmaceuticals announced that the Ministry of Corporate Affairs, Government of Indi...

Read more

08 May 2025 09:39

News

Suven Pharmaceuticals receives regulatory nod for scheme of amalgamation

Suven Pharmaceuticals announced that it has received final approval from the Department of...

Read more

26 Apr 2025 12:56

News

Suven Pharmaceuticals to table results

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 M...

Read more

27 Mar 2025 09:42

News

Suven Pharmaceuticals receives credit ratings from CRISIL

Suven Pharmaceuticals announced that CRISIL has assigned/ reaffirmed the following ratings...

Read more

28 Feb 2025 19:46

Sanofi India Ltd News Hub

News

Sanofi India to hold board meeting

Sanofi India will hold a meeting of the Board of Directors of the Company on 14 May 2025. ...

Read more

10 May 2025 10:52

News

Sanofi India MD Rodolfo Hrosz resigns

The board of directors accepted Hrosz's resignation during a meeting held on 9 April and e...

Read more

11 Apr 2025 11:01

News

Sanofi India to convene AGM

Sanofi India announced that the 69th Annual General Meeting(AGM) of the company will be he...

Read more

19 Mar 2025 12:01

News

Board of Sanofi India recommends final dividend

Sanofi India announced that the Board of Directors of the Company at its meeting held on 2...

Read more

28 Feb 2025 09:13

News

Board of Schaeffler India recommends Final Dividend

Schaeffler India announced that the Board of Directors of the Company at its meeting held ...

Read more

27 Feb 2025 17:28

News

Sanofi India to conduct board meeting

Sanofi India will hold a meeting of the Board of Directors of the Company on 27 February 2...

Read more

14 Feb 2025 09:41

SWOT Analysis Of Sanofi India Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Suven Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Sanofi India Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Suven Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Suven Pharmaceuticals Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Suven Pharmaceuticals Ltd or Sanofi India Ltd?

Market cap of Suven Pharmaceuticals Ltd is 25,975 Cr while Market cap of Sanofi India Ltd is 14,215 Cr

What are the key factors driving the stock performance of Suven Pharmaceuticals Ltd and Sanofi India Ltd?

The stock performance of Suven Pharmaceuticals Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Suven Pharmaceuticals Ltd and Sanofi India Ltd?

As of June 4, 2025, the Suven Pharmaceuticals Ltd stock price is INR ₹1020.4. On the other hand, Sanofi India Ltd stock price is INR ₹6172.8.

How do dividend payouts of Suven Pharmaceuticals Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Suven Pharmaceuticals Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions